Top-Rated StocksTop-RatedNASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis → On June 10, Nvidia makes its next big move (From Weiss Ratings) (Ad) Free IDYA Stock Alerts $36.55 +0.76 (+2.12%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$35.87▼$37.4150-Day Range$35.79▼$43.8852-Week Range$20.90▼$47.74Volume973,584 shsAverage Volume805,591 shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$46.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get IDEAYA Biosciences alerts: Email Address IDEAYA Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside28.0% Upside$46.80 Price TargetShort InterestBearish16.42% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.40Based on 16 Articles This WeekInsider TradingSelling Shares$4.83 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.37) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector305th out of 928 stocksPharmaceutical Preparations Industry138th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIDEAYA Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about IDEAYA Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.42% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently increased by 3.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEAYA Biosciences has received a 72.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEAYA Biosciences is -0.79. Previous Next 2.4 News and Social Media Coverage News SentimentIDEAYA Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,832,228.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.37) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -18.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -18.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IDEAYA Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About IDEAYA Biosciences Stock (NASDAQ:IDYA)IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More IDYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDYA Stock News HeadlinesJune 1 at 8:53 AM | insidertrades.comInsider Selling: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Insider Sells 28,500 Shares of StockMay 17, 2024 | insidertrades.comInsider Selling: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) CEO Sells 34,433 Shares of StockMay 31 at 6:00 AM | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29 at 6:00 AM | prnewswire.comIDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations EventsMay 28, 2024 | finanznachrichten.deIDEAYA Biosciences, Inc.: IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business DevelopmentMay 28, 2024 | prnewswire.comIDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business DevelopmentMay 27, 2024 | americanbankingnews.comFY2028 EPS Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Cut by Capital One FinancialMay 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)May 24, 2024 | markets.businessinsider.comBuy Rating on IDEAYA Biosciences: Darovasertib’s Market Potential and Promising Clinical ResultsMay 23, 2024 | finance.yahoo.com/C O R R E C T I O N -- IDEAYA Biosciences, Inc./May 23, 2024 | prnewswire.comIDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal MelanomaMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for IDEAYA Biosciences Amid Promising Clinical Updates and Pipeline CatalystsMay 8, 2024 | markets.businessinsider.comUnveiling 5 Analyst Insights On IDEAYA BiosciencesMay 8, 2024 | finance.yahoo.comIDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: IDEAYA Biosciences’ Promising Pipeline and Strong Financial PositionMay 7, 2024 | investorplace.comIDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comIDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 7, 2024 | prnewswire.comIDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventApril 26, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyApril 22, 2024 | prnewswire.comIDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerApril 5, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventMarch 20, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IDYASee More Headlines Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/01/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IDYA CUSIPN/A CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Target$46.80 High Stock Price Target$60.00 Low Stock Price Target$33.00 Potential Upside/Downside+28.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-483.05% Pretax Margin-831.30% Return on Equity-20.09% Return on Assets-19.30% Debt Debt-to-Equity RatioN/A Current Ratio28.42 Quick Ratio28.42 Sales & Book Value Annual Sales$23.39 million Price / Sales118.28 Cash FlowN/A Price / Cash FlowN/A Book Value$12.36 per share Price / Book2.96Miscellaneous Outstanding Shares75,690,000Free Float73,038,000Market Cap$2.77 billion OptionableOptionable Beta0.83 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Yujiro S. Hata (Age 50)President, CEO & Director Comp: $912kMr. Andres Ruiz Briseno CPA (Age 38)Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations Comp: $485.12kDr. Michael A. White Ph.D. (Age 58)Chief Scientific Officer Comp: $661.8kMr. Jason S. Throne Esq. (Age 52)J.D., Chief Legal Officer & Company Secretary Comp: $598.8kDr. Darrin M. Beaupre M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $665.58kDr. Paul A. Barsanti Ph.D.Chief Technology OfficerMr. Mick O'QuigleyChief of Staff & Clinical DevelopmentMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXSyros PharmaceuticalsNASDAQ:SYRSCue BiopharmaNASDAQ:CUEOsmotica PharmaceuticalsNASDAQ:OSMTSarepta TherapeuticsNASDAQ:SRPTView All CompetitorsInsiders & InstitutionsMichael Anthony WhiteSold 28,500 sharesTotal: $1.03 M ($36.24/share)Boston PartnersBought 13,391 shares on 5/28/2024Ownership: 0.018%Farallon Capital Management LLCBought 5,000 shares on 5/24/2024Ownership: 0.007%Comerica BankBought 1,324 shares on 5/17/2024Ownership: 0.002%Redmile Group LLCSold 13,185 shares on 5/16/2024Ownership: 1.219%View All Insider TransactionsView All Institutional Transactions IDYA Stock Analysis - Frequently Asked Questions Should I buy or sell IDEAYA Biosciences stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares. View IDYA analyst ratings or view top-rated stocks. What is IDEAYA Biosciences' stock price target for 2024? 12 brokerages have issued 12-month target prices for IDEAYA Biosciences' shares. Their IDYA share price targets range from $33.00 to $60.00. On average, they expect the company's stock price to reach $46.80 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts. How have IDYA shares performed in 2024? IDEAYA Biosciences' stock was trading at $35.58 at the beginning of the year. Since then, IDYA stock has increased by 2.7% and is now trading at $36.55. View the best growth stocks for 2024 here. When is IDEAYA Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our IDYA earnings forecast. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.02. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 20.09% and a negative net margin of 483.05%. The company's revenue for the quarter was down 100.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.49) EPS. What ETFs hold IDEAYA Biosciences' stock? ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Jacob Forward ETF (JFWD), Loncar China Biopharma ETF (CHNA), Range Cancer Therapeutics ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI) and Tema Oncology ETF (CANC). What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA). When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.56%), Price T Rowe Associates Inc. MD (5.35%), Janus Henderson Group PLC (5.03%), BVF Inc. IL (1.54%), Redmile Group LLC (1.22%) and First Light Asset Management LLC (0.44%). Insiders that own company stock include Briseno Andres Ruiz, Jason Throne, Michael Anthony White, Michael P Dillon, Michael P Dillon, Paul A Stone and Yujiro S Hata. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IDYA) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
